220 related articles for article (PubMed ID: 28342104)
1. A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment.
Ryall S; Tabori U; Hawkins C
Brain Tumor Pathol; 2017 Apr; 34(2):51-61. PubMed ID: 28342104
[TBL] [Abstract][Full Text] [Related]
2. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
[TBL] [Abstract][Full Text] [Related]
3. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF
Ellison DW; Hawkins C; Jones DTW; Onar-Thomas A; Pfister SM; Reifenberger G; Louis DN
Acta Neuropathol; 2019 Apr; 137(4):683-687. PubMed ID: 30848347
[No Abstract] [Full Text] [Related]
4. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
Qaddoumi I; Orisme W; Wen J; Santiago T; Gupta K; Dalton JD; Tang B; Haupfear K; Punchihewa C; Easton J; Mulder H; Boggs K; Shao Y; Rusch M; Becksfort J; Gupta P; Wang S; Lee RP; Brat D; Peter Collins V; Dahiya S; George D; Konomos W; Kurian KM; McFadden K; Serafini LN; Nickols H; Perry A; Shurtleff S; Gajjar A; Boop FA; Klimo PD; Mardis ER; Wilson RK; Baker SJ; Zhang J; Wu G; Downing JR; Tatevossian RG; Ellison DW
Acta Neuropathol; 2016 Jun; 131(6):833-45. PubMed ID: 26810070
[TBL] [Abstract][Full Text] [Related]
5. Pediatric low-grade glioma in the era of molecular diagnostics.
Ryall S; Tabori U; Hawkins C
Acta Neuropathol Commun; 2020 Mar; 8(1):30. PubMed ID: 32164789
[TBL] [Abstract][Full Text] [Related]
6. New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model.
Raabe E; Kieran MW; Cohen KJ
Clin Cancer Res; 2013 Sep; 19(17):4553-8. PubMed ID: 23881924
[TBL] [Abstract][Full Text] [Related]
7. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
Nobusawa S; Hirato J; Yokoo H
Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
[TBL] [Abstract][Full Text] [Related]
10. Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers.
Nakao T; Sasagawa Y; Nobusawa S; Takabatake Y; Sabit H; Kinoshita M; Miyashita K; Hayashi Y; Yokoo H; Nakada M
Brain Tumor Pathol; 2017 Oct; 34(4):149-154. PubMed ID: 28795231
[TBL] [Abstract][Full Text] [Related]
11. Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification.
Komori T
Brain Tumor Pathol; 2020 Jan; 37(1):1-4. PubMed ID: 32060660
[No Abstract] [Full Text] [Related]
12. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
13. Pediatric low-grade gliomas and the need for new options for therapy: Why and how?
Qaddoumi I; Sultan I; Broniscer A
Cancer Biol Ther; 2009 Jan; 8(1):4-10. PubMed ID: 19164945
[TBL] [Abstract][Full Text] [Related]
14. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
15. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.
Wefers AK; Stichel D; Schrimpf D; Coras R; Pages M; Tauziède-Espariat A; Varlet P; Schwarz D; Söylemezoglu F; Pohl U; Pimentel J; Meyer J; Hewer E; Japp A; Joshi A; Reuss DE; Reinhardt A; Sievers P; Casalini MB; Ebrahimi A; Huang K; Koelsche C; Low HL; Rebelo O; Marnoto D; Becker AJ; Staszewski O; Mittelbronn M; Hasselblatt M; Schittenhelm J; Cheesman E; de Oliveira RS; Queiroz RGP; Valera ET; Hans VH; Korshunov A; Olar A; Ligon KL; Pfister SM; Jaunmuktane Z; Brandner S; Tatevossian RG; Ellison DW; Jacques TS; Honavar M; Aronica E; Thom M; Sahm F; von Deimling A; Jones DTW; Blumcke I; Capper D
Acta Neuropathol; 2020 Jan; 139(1):193-209. PubMed ID: 31563982
[TBL] [Abstract][Full Text] [Related]
16. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.
Horbinski C; Nikiforova MN; Hagenkord JM; Hamilton RL; Pollack IF
Neuro Oncol; 2012 Jun; 14(6):777-89. PubMed ID: 22492957
[TBL] [Abstract][Full Text] [Related]
17. A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF
Sadashima S; Suzuki SO; Haruyama H; Mukae N; Fujioka Y; Hata N; Mizoguchi M; Ishimatsu K; Hiwatashi A; Iwaki T
Neuropathology; 2020 Dec; 40(6):646-650. PubMed ID: 32996219
[TBL] [Abstract][Full Text] [Related]
18. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
